MiR-380 inhibits the proliferation and invasion of cholangiocarcinoma cells by silencing LIS1

被引:0
作者
Wei, Zhicheng [1 ,2 ,3 ]
Xu, Bowen [1 ,4 ]
Yin, Yanjiang [1 ,4 ]
Chang, Jianping [1 ]
Li, Zhiyu [1 ]
Zhang, Yefan [1 ]
Che, Xu [2 ,3 ]
Bi, Xinyu [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Hepatobiliary Surg,Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Hepatobiliary & Pancreat Surg, Natl Canc Ctr,Natl Clin Res Ctr Canc, Shenzhen 518116, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen 518116, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Key Lab Gene Editing Screening & Res & Dev R&D Dig, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China
关键词
Cholangiocarcinoma; miR-380; LIS1; CANCER-ASSOCIATED FIBROBLASTS; HEPATOCELLULAR-CARCINOMA; FATTY LIVER; NOMOGRAM; THERAPY; NETWORK;
D O I
10.1186/s12935-024-03241-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The objective of this study was to determine the role and regulatory mechanism of miR-380 in cholangiocarcinoma.Methods The TargetScan database and a dual-luciferase reporter assay system were used to determine if LIS1 was a target gene of miR-380. The Cell Counting Kit 8 assay, flow cytometry, and Transwell assay were used to detect the effects of miR-380 and LIS1 on the proliferation, S-phase ratio, and invasiveness of HCCC-9810/HuCCT1/QBC939 cells. Western blotting was used to determine the effect of miR-380 on MMP-2/p-AKT. Immunohistochemistry detected the regulatory effect of miR-380 on the expression of MMP-2/p-AKT/LIS1.Results Expression of miR-380 in cholangiocarcinoma was decreased but expression of LIS1 was increased. LIS1 was confirmed to be a target gene of miR-380. Transfection with miR-380 mimics inhibited the proliferation, S-phase arrest, and invasion of HCCC-9810/HuCCT1/QBC939 cells, and LIS1 reversed these inhibitory effects. miR-380 inhibitor promoted proliferation, S-phase ratio, and invasiveness of HCCC-9810/HuCCT1/QBC939 cells. si-LIS1 salvaged the promotive effect of miR-380 inhibitor. Overexpression of miR-380 inhibited expression of MMP-2/p-AKT/LIS1, but miR-380 inhibitor promoted their expression.Conclusion An imbalance of miR-380 expression is closely related to cholangiocarcinoma, and overexpression of miR-380 inhibits the expression of MMP-2/p-AKT by directly targeting LIS1.
引用
收藏
页数:11
相关论文
共 37 条
  • [1] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
    Abou-Alfa, Ghassan K.
    Sahai, Vaibhav
    Hollebecque, Antoine
    Vaccaro, Gina
    Melisi, Davide
    Al-Rajabi, Raed
    Paulson, Andrew S.
    Borad, Mitesh J.
    Gallinson, David
    Murphy, Adrian G.
    Oh, Do-Youn
    Dotan, Efrat
    Catenacci, Daniel, V
    Van Cutsem, Eric
    Ji, Tao
    Lihou, Christine F.
    Zhen, Huiling
    Feliz, Luis
    Vogel, Arndt
    [J]. LANCET ONCOLOGY, 2020, 21 (05) : 671 - 684
  • [2] The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
    Affo, Silvia
    Yu, Le-Xing
    Schwabe, Robert F.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 12, 2017, 12 : 153 - 186
  • [3] Bray Freddie, 2018, CA Cancer J Clin, V68, P394, DOI [10.3322/caac.21609, 10.3322/caac.21492]
  • [4] Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
    Banales, Jesus M.
    Cardinale, Vincenzo
    Carpino, Guido
    Marzioni, Marco
    Andersen, JesperB.
    Invernizzi, Pietro
    Lind, Guro E.
    Folseraas, Trine
    Forbes, Stuart J.
    Fouassier, Laura
    Geier, Andreas
    Calvisi, Diego F.
    Mertens, Joachim C.
    Trauner, Michael
    Benedetti, Antonio
    Maroni, Luca
    Vaquero, Javier
    Macias, Rocio I. R.
    Raggi, Chiara
    Perugorria, Maria J.
    Gaudio, Eugenio
    Boberg, Kirsten M.
    Marin, Jose J. G.
    Alvaro, Domenico
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (05) : 261 - 280
  • [5] Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
    Cereda, S.
    Milella, M.
    Cordio, S.
    Leone, F.
    Aprile, G.
    Galiano, A.
    Mosconi, S.
    Vasile, E.
    Santini, D.
    Belli, C.
    Auriemma, A.
    Novarino, A.
    Vaccaro, V.
    Martines, C.
    Marino, D.
    Lutrino, S. E.
    Palazzo, V.
    Reinach, B.
    Aldrighetti, L.
    Reni, M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (01) : 109 - 114
  • [6] MicroRNA-129-2-3p directly targets Wip1 to suppress the proliferation and invasion of intrahepatic cholangiocarcinoma
    Chen, Chen
    Jiang, Jinqiong
    Fang, Meng
    Zhou, Lei
    Chen, Yongzhi
    Zhou, Jia
    Song, Yinghui
    Kong, Gaoying
    Zhang, Bao
    Jiang, Bo
    Li, Hao
    Peng, Chuang
    Liu, Sulai
    [J]. JOURNAL OF CANCER, 2020, 11 (11): : 3216 - 3224
  • [7] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [8] MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8
    Chen, Yalin
    Bian, Li
    Zhang, Yingmei
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2018, 70 (07) : 937 - 951
  • [9] Weighted correlation network analysis revealed novel long non-coding RNAs for colorectal cancer
    Chodary Khameneh, Sepideh
    Razi, Sara
    Shamdani, Sara
    Uzan, Georges
    Naserian, Sina
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [10] Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
    Clements, Oliver
    Eliahoo, Joseph
    Kim, Jin Un
    Taylor-Robinson, Simon D.
    Khan, Shahid A.
    [J]. JOURNAL OF HEPATOLOGY, 2020, 72 (01) : 95 - 103